根据美国证券交易委员会的一份文件显示，Natera, Inc.（纳斯达克股票代码：NTRA）的执行董事长Matthew Rabinowitz最近出售了大量公司股票。该公司股票今年以来已上涨超过165%，目前在52周高点附近交易，价格为166.55美元。根据 InvestingPro ...

Natera (NTRA) announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

Natera has begun the subject enrolment in the randomised Phase III SAGITTARIUS clinical trial designed to assess the ...

JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Natera (NTRA) to $200 from $160 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect ...

Currently trading with a volume of 643,596, the NTRA's price is up by 3.63%, now at $172.49. RSI readings suggest the stock ...

德克萨斯州奥斯汀讯——根据向美国证券交易委员会提交的4表格显示，Natera, Inc.（纳斯达克股票代码：NTRA）临床诊断总裁Solomon Moshkevich最近进行了一笔重大的公司股票交易。Moshkevich于2024年12月9日以加权平均价格166.5937美元每股的价格出售了4,858股Natera普通股。此次出售的总价值约为809,312美元。根据 InvestingPro ...

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the SAGITTARIUS clinical trial. Sponsored by The AIRC ...

The latest announcement is out from Natera ( (NTRA) ).

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome ...

According to Benzinga Pro, Natera's peer group average for short interest as a percentage of float is 5.09%, which means the ...

Natera has a 52-week low of $55.56 and a 52-week high of $171.95. The stock has a market cap of $22.33 billion, a price-to-earnings ratio of -96.12 and a beta of 1.63.